BioMarin Pharmaceuticals BMRN Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $766.21M+2.8% | $874.57M+17.0% | $776.13M+4.1% | $825.41M+15.9% | $745.15M+14.8% | ||
| $195M+28.7% | $275.71M+103% | $140.09M-25.7% | $150.09M+15.0% | $151.56M+21.1% | ||
| $571.21M-3.8% | $598.86M-2.0% | $636.05M+14.1% | $675.32M+16.1% | $593.59M+13.4% | ||
| 74.6%-5.1pp | 68.5%-13.3pp | 82%+7.2pp | 81.8%+0.1pp | 79.7%-1.0pp | ||
| $178.8M+12.6% | $192.41M+10.9% | $409.48M+121% | $161.31M-12.2% | $158.73M-22.6% | ||
| $258.29M+25.3% | $446.21M+67.4% | $268.42M+5.9% | $232.28M-11.7% | $206.12M-8.8% | ||
| $43.46M+15.3% | —— | $49.27M+13.3% | $47.53M-0.8% | $37.7M-35.3% | ||
| $16.41M-25.6% | $20.44M-13.4% | $18.49M-2.7% | $18.56M-29.9% | $22.07M-19.3% | ||
| $0-100% | —— | —— | —— | $2.97M— | ||
| $3.96M+303% | $1.03M+115% | $5.09M-6.8% | $4.83M+207% | -$1.95M-254% | ||
| $636.57M+22.1% | $919.18M+56.9% | $822.83M+30.2% | $548.52M-7.3% | $521.25M-7.0% | ||
| $129.64M-42.1% | —— | -$46.69M-141% | $276.89M+130% | $223.89M+153% | ||
| 16.9%-13.1pp | —— | -6%-21.3pp | 33.5%+16.6pp | 30%+16.4pp | ||
| $14.96M+422% | $2.78M+7.8% | $2.58M-13.1% | $2.68M-25.0% | $2.86M-19.3% | ||
| $22.56M+18.7% | $19.21M+8.7% | $17.85M-1.1% | $18.83M-4.8% | $19.01M-1.8% | ||
| $5.37M+324% | —— | —— | $649K-34.1% | $1.27M+1,098% | ||
| $141.2M-40.7% | $0-100% | -$26.32M-120% | $297.87M+125% | $238.09M+126% | ||
| $35.68M-31.9% | $19.42M-56.6% | $4.42M-84.4% | $57.34M+130% | $52.4M+210% | ||
| $105.53M-43.2% | —— | -$30.74M-129% | $240.53M+124% | $185.69M+109% | ||
| 13.8%-11.1pp | —— | -4%-18.2pp | 29.1%+14.1pp | 24.9%+11.3pp | ||
| $0.54-43.2% | —— | -$0.16-129% | $1.23+124% | $0.95+107% | ||
| $0.55-43.3% | —— | -$0.16-129% | $1.25+123% | $0.97+106% | ||
| 197.7M+0.6% | 197.4M+0.3% | 192M-2.6% | 197.1M-1.7% | 196.5M-1.4% | ||
| 192.5M+0.8% | 191.8M+0.9% | 192M+0.8% | 191.9M+0.9% | 191M+1.1% | ||
| $455K-66.6% | —— | $978K-49.6% | $1.36M-37.7% | $1.36M-45.6% | ||
| $43.46M+15.3% | —— | $49.27M+13.3% | $47.53M-0.8% | $37.7M-35.3% | ||
| $487K+0.4% | —— | —— | —— | $485K— | ||
| $279K+933% | —— | —— | —— | $27K— | ||
| $6.09M+822% | $653K-1.1% | $649K-9.6% | $660K-33.4% | $660K-33.3% | ||
| $4.48M-7.5% | $4.85M-49.8% | $4.85M-3.2% | $4.85M-66.1% | $4.85M-66.1% | ||
| 13.8M+18.1% | —— | 16.8M+78.0% | —— | 11.7M+6.8% | ||
| $11.2M+151% | —— | —— | —— | $4.47M+377% | ||
| $4.48M— | —— | —— | —— | $0— | ||
| $1.76B+1,562% | —— | $36.29M+112% | $165.01M-26.7% | $105.96M+1,403% | ||
| -$5M+69.1% | —— | —— | -$19.8M— | -$16.2M— | ||
| $114.76M-19.8% | —— | -$20.12M-124% | $176.82M+31.0% | $143.18M+23.0% | ||
| $9.22M-67.6% | $613K-98.6% | —— | $33.34M+2,563% | $28.43M+9,875% | ||
| $8.8M-37.6% | —— | $10.6M-2.8% | $10.6M-7.8% | $14.1M+11.9% | ||
| $1.41M+200% | —— | —— | -$3.06M-193% | -$1.42M-173% | ||
| -$6.71M-167% | —— | -$5.55M-332% | —— | $10.03M-7.2% | ||
| $14.64M+41.0% | $26M+22.7% | $7.82M-40.8% | $52M+153% | $10.39M+351% | ||
| $3.1M+217% | —— | $116.37M-4.8% | $5.77M— | -$2.66M+95.5% | ||
| $7.16M-87.6% | $120.68M— | —— | $98.53M+87.0% | $57.59M+1,601% | ||
| -$44.49M-283% | $18.13M-47.1% | $26.33M— | $48.13M+57.3% | $24.34M+44.7% | ||
| $11.55M+82.6% | -$41.02M— | $17.03M-21.0% | $8.77M+146% | $6.33M-63.5% | ||
| -$1.48M-191% | $5.89M-85.9% | $19.17M+114% | $11.88M+10.5% | $1.62M-86.6% | ||
| $8.7M+321% | —— | $16.36M+365% | $3.47M+2.0% | $2.07M-37.5% | ||
| $8.81M+370% | —— | —— | —— | $1.88M— | ||
| $1.83M+0.1% | —— | $0-100% | $1.83M-33.8% | $1.83M-33.8% | ||
| $813.17M+2,197% | $0— | -$2.17M+99.6% | -$4.6M— | -$38.78M+9.4% | ||
| $725.53M+2,669% | -$42.45M-156% | -$330.96M— | -$12.59M-114% | -$28.24M-98.4% | ||
| $220.65M+26.5% | $99.64M-46.3% | $368.69M+66.5% | $185.27M+56.0% | $174.39M+271% | ||
| 10.0% | —— | —— | —— | 10.0% | ||
| 1— | —— | —— | —— | —— | ||
| -$699K+97.8% | —— | $2.65M+116% | -$64.17M-308% | -$32.22M-221% | ||
| $9.24M+122% | —— | $10.63M+148% | -$63.72M-329% | -$42.5M-253% | ||
| -$1.12M-426% | —— | $157K-93.1% | $94K+159% | $345K+168% | ||
| $5.37M+324% | $2.71M+113% | $0-100% | $649K-34.1% | $1.27M+1,098% | ||
| $3.96M+303% | $1.03M+115% | $5.09M-6.8% | $4.83M+207% | -$1.95M-254% | ||
| -$4.97M— | $0+100% | —— | —— | $0+100% | ||
| $8.65M— | —— | —— | —— | $0— | ||
| $28.18M-27.3% | $2.7M-45.0% | $2.18M-63.2% | $12.31M-26.7% | $38.78M-22.4% | ||
| $25.79M-71.1% | $42.61M-26.4% | $110.83M-29.4% | $113.16M+53.3% | $89.27M-26.6% | ||
| $20.92M+24.8% | $40.72M+109% | $28.45M+54.1% | $17.1M-19.8% | $16.77M-35.8% | ||
| $850M— | —— | —— | —— | $0— | ||
| $767.28M+886% | $43.25M-72.0% | $98.81M-38.5% | $117.93M-36.6% | $77.8M-40.8% | ||
| -$8.81M-189% | —— | -$8.14M-330% | -$549K-117% | $9.94M+1,716% | ||
| $766.21M+2.8% | $874.57M+17.0% | $776.13M+4.1% | $825.41M+15.9% | $745.15M+14.8% | ||
| $43.46M+15.3% | $46.91M-9.6% | $49.27M+13.3% | $47.53M-0.8% | $37.7M-35.3% | ||
| $129.64M-42.1% | $2.78M-98.3% | -$46.69M-141% | $276.89M+130% | $223.89M+153% | ||
| $146.05M-40.6% | $23.22M-87.5% | -$28.21M-121% | $295.45M+101% | $245.96M+112% | ||
| $146.05M-40.6% | $23.22M-87.5% | -$28.21M-121% | $295.45M+101% | $245.96M+112% | ||
| 19.1%-13.9pp | 2.7%-22.1pp | -3.6%-21.5pp | 35.8%+15.2pp | 33%+15.2pp | ||
| $129.64M-42.1% | $2.78M-98.3% | -$46.69M-141% | $276.89M+130% | $223.89M+153% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is BioMarin Pharmaceuticals's revenue?
- BioMarin Pharmaceuticals (BMRN) generated $3.2B in revenue over the trailing twelve months, up 9.9% year over year.
- Is BioMarin Pharmaceuticals profitable?
- BioMarin Pharmaceuticals reported $501.0M in net income over the trailing twelve months, a 16.8% net margin.
- What are BioMarin Pharmaceuticals's profit margins?
- Gross margin is 76.5% and operating margin is 19.9%, with a 16.8% net margin.
- What is BioMarin Pharmaceuticals's earnings per share?
- BioMarin Pharmaceuticals's diluted EPS over the trailing twelve months is $2.56.
- Where does BioMarin Pharmaceuticals's income statement data come from?
- Every line is extracted from BioMarin Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
